PIQ proteomics international laboratories ltd

I think it's an accurate account of where Promarker D sits at...

  1. 632 Posts.
    lightbulb Created with Sketch. 168
    I think it's an accurate account of where Promarker D sits at the moment. The test is probably more relevant to those at a higher risk of developing diabetic kidney disease which a treating doctor would be aware of. 1 in 3 diabetics progress to DKD which is a significant number. Whilst the cost for the test in Spain is relatively high it's not prohibitive and shouldn't have a material affect on take up. PIQ has recognised sales will start slowly and then gradually build up, patients may only see their doctor a few times a year.

    It will also differ in countries/jurisdictions depending on how much they are prepared to do to address the disease. The US has made it a priority.

    Then there's other potential near term opportunities Promarker D may become a companion test for a drug, or used in clinical trials for new new drugs.

    In the meantime PIQ has another arm of revenue its Analytical Services which is growing and could become a meaningful revenue stream.

    Plus ongoing research for further diagnostic tests.

    A market cap of $26M seems very low but it won't take much to move the SP the stock is pretty tightly held. And as more of the potential is realised a takeover becomes more probable.



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
30.5¢
Change
-0.020(6.15%)
Mkt cap ! $50.69M
Open High Low Value Volume
33.5¢ 34.5¢ 28.5¢ $201.7K 642.4K

Buyers (Bids)

No. Vol. Price($)
1 3253 30.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 57411 2
View Market Depth
Last trade - 16.10pm 25/06/2025 (20 minute delay) ?
PIQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.